KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Novartis Ag (NVS) R&D In Process (2023 - 2026)

Novartis Ag's R&D In Process history spans 3 years, with the latest figure at $11.3 billion for Q1 2026.

  • On a quarterly basis, R&D In Process changed N/A to $11.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $11.3 billion, a N/A change, with the full-year FY2024 number at $1.7 billion, down 43.23% from a year prior.
  • R&D In Process hit $11.3 billion in Q1 2026 for Novartis Ag, up from $1.7 billion in the prior quarter.
  • Over the last five years, R&D In Process for NVS hit a ceiling of $11.3 billion in Q1 2026 and a floor of $1.7 billion in Q4 2024.
  • Historically, R&D In Process has averaged $4.4 billion across 3 years, with a median of $2.3 billion in 2023.
  • The widest YoY moves for R&D In Process: up 43.23% in 2024, down 43.23% in 2024.
  • Tracing NVS's R&D In Process over 3 years: stood at $2.9 billion in 2023, then crashed by 43.23% to $1.7 billion in 2024, then surged by 579.09% to $11.3 billion in 2026.
  • Business Quant data shows R&D In Process for NVS at $11.3 billion in Q1 2026, $1.7 billion in Q4 2024, and $1.7 billion in Q2 2024.